Stabilization of mismatch repair gene PMS2 by glycogen synthase kinase 3β is implicated in the treatment of cervical carcinoma
© Zhang et al; licensee BioMed Central Ltd. 2010
Received: 14 May 2009
Accepted: 23 February 2010
Published: 23 February 2010
PMS2 expression loss was reported in a variety of human. However, its importance has not been fully understood in cervical carcinoma. The aim of this study was to determine the expression of PMS2 in cervical carcinoma and evaluate the significance of mismatch repair gene PMS2 regulated by glycogen synthase kinase 3β (GSK-3β) in chemosensitivity.
We examined PMS2 and phosphorylated GSK-3β(s9) expression in cervical carcinoma tissues using immunohistochemical staining. Furthermore, we detected PMS2 expression in HeLa cells and evaluate the interaction with GSK-3β after transfection with GSK-3β by small interference RNA (siRNA), co-immunoprecipitation and immunoblotting. We also evaluated the effect of PMS2 transfection on HeLa cells' chemosensitivity to cisplatin treatment.
We found significant downregulation of PMS2 in cervical carcinoma, which was negatively associated with phosphorylated GSK-3β (s9). Furthermore, we demonstrated GSK-3β transfection was able to interact with PMS2 and enhance PMS2 production in HeLa cells, and increased PMS2 production was responsible for enhanced chemosensitivity.
Our results provide the evidence that stabilization of PMS2 production by GSK-3β was important to improve chemosensitization, indicating the significance of GSK-3β-related PMS2 downregulation in the development of cervical carcinoma and in developing a potential strategy for chemotherapy.
Globally, cervical cancer is second only to breast cancer as the leading cause of cancer death in women, with a prevalence of 2.3 million cases and an annual incidence of half million . And approximately 275,000 women die from this disease every year worldwide . Despite advances in the study of cervical cancer over the past 20 years, its pathogenesis is still not fully understood .
Mismatch repair (MMR) is one of the most important DNA repair processes for maintaining genetic fidelity. MMR deficiency leads to carcinogenesis through increased mutation frequency, loss of cell cycle arrest, and decreased apoptosis in response to DNA damage. In addition to MSH2 and MLH1, other human mismatch repair genes including MSH3, MSH6, MLH3, PMS1, and PMS2 have been identified . To date, a disrupted MMR system has been identified in several cancers, including hereditary nonpolyposis colorectal cancer (HNPCC), and some sporadic cancers . The bulk of germline HNPCC mutations, roughly 90%, resides in two MMR genes, MSH2 and MLH1, with mutations in MSH6 (7-10%) associated with atypical HNPCC . However, PMS2 mutations are quite rare in HNPCC as well as various other cancers [7–9].
It is very important to recognize that aberrant expression of MMR proteins has been reported to be associated with increased risk of cervical cancer , low and loss of expression of MMR in patients with cervical cancer has been described by different groups as well. For instance, Chung et al. showed loss of MSH2 expression in 7 of 50 squamous cervical cancers , and Giarnieri et al. showed loss of MSH2 in 10 of 23 cervical cancers . Ciavattini et al. recently found MSH2 and MLH1 expression to be lower in 28 invasive squamous cervical cancers compared to cervical intraepithelial lesions . These findings therefore implied that MMR may be also associated with the pathogenesis of cervical cancer. The PMS2 gene encodes a MutL-homologous protein that forms a heterodimer with MLH1, and the resulting complex, MutLα, interacts with MutSα/β to activate MMR. Because monomeric PMS2 is highly unstable , and the reported mutation rate of PMS2 is quite low in various cancers, we hypothesized that certain types of exogenous DNA-damaging agents may rapidly degrade PMS2 production and disrupt the MMR system for facilitating carcinogenesis. Given that few data are available regarding PMS2 modulation in human cervical carcinoma, investigating the mechanisms underlying the regulation of PMS2 may be essential for understanding the significance of PMS2 in carcinogenesis.
To address this issue, we focused on the possibility of modulation of MMR proteins by taking advantage of Wnt signaling activation in this study, since certain key components such as Glycogen synthase kinase 3β (GSK-3β) in Wnt signaling have been implicated in a number of cancers . GSK-3β is active in resting cells, and it is modulated by site-specific phosphorylation at the site of s9 (inactivation) during cellular responses. We chose GSK-3β and PSM2 in this study mainly because germline PMS2 mutations are rarely reported, unlike other components. On the other hand, our preliminary findings demonstrated a consensus motif of VSSSH GPSDP TDRAE in PMS2 (s499) by gene sequencing. This consensus motif was shown to be the common phosphorylation motif recognized and activated by GSK-3β in previous studies . Our preliminary finding thus provides the possibility that the interaction of GSK-3β with the PMS2 consensus motif contributes to maintaining genomic stability and promoting protective responses of mammalian cells to exogenous DNA damage (e.g., apoptosis). If so, the rapid induction and degradation of PMS2 may be essential in the balance between cell survival and death as a sensor of environmental changes in cervical carcinoma.
To verify this hypothesis, we examined the expression of PSM2 protein in cervical cancer in this study, evaluated the effects of cisplatin on PMS2 expression in HeLa cells, and examined the importance of GSK-3β binding on PMS2 stability and chemosensitization to cisplatin in HeLa cells by taking advantage of co-immunoprecipitation (IP), small interference RNA (siRNA) and flow cytometric analysis. Our finding therefore will be helpful in clarifying the molecular mechanisms involving the modulation of MMR proteins by Wnt signaling in the development of cervical carcinoma and in developing a possible therapeutic target for future chemotherapy.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), cisplatin (cis-diammine-dichloroplatinum), dimethyl sulfoxide (DMSO), and lithium chloride (LiCl), a GSK-3β inhibitor, were purchased from Sigma. Human pGSK-3β (s9) and β-actin antibody were obtained from Santa Cruz Biotech. MLH1, MSH2, and PSM2 antibody was obtained from BD Biosciences. The plasmids pCGN-GSK-3β (WT), pGEX-GSK-3β, constitutively active GSK-3β (GSK-3β-CA; S9A GSK-3β), kinase-dead GSK-3β (GSK-3β-KD; pCGN-GSK-3β-KD) plasmids and pCGN-PMS2 plasmids were kindly provided by Dr. Qingqing Ding (MD Anderson Cancer Center, Houston, USA). Plasmid vector GSK-3β siRNA (pKD-GSK-3β-V1;Si-GSk-3β) was purchased from Upstate Biotechnology. Enhanced chemiluminescence western blotting detection reagents were purchased from Cell Signaling. Transfection reagents (Lipofectamine 2000 and PLUS reagent) were purchased from Invitrogen Corporation.
For immunohistochemical staining, seventy-eight surgically resected human cervical carcinoma tissues were collected from the Departments of Obstetrics and Gynecology, Wuhan Union Hospital, and the study was approved by the institutional review board. Immunohistochemistry was performed according to our previously described protocol . Briefly, human tumor tissues embedded in paraffin were cut into 5-μm sections and placed onto glass slides. After antigen retrieval, sections were stained for the expression of MLH1 (1:50), MSH2 (1:50), PMS2 (1:100), and pGSK-3β (1:100), and then detected by streptavidin-biotin-horseradish peroxidase complex formation. Tumor sections stained by isotype matched IgG instead of primary antibodies were used as a negative control. The immunostaining was considered positive when the tumour mass occupied more than 10% of the cross-sectional core area and when 10% or more of the neoplastic cells were stained.
Human cervical carcinoma HeLa cell lines (American Type Culture Collection) were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS) (Invitrogen), penicillin (100 units/mL), and streptomycin (100 μg/mL; Invitrogen). All cultures were maintained at 37°C in a humidified atmosphere with 5% CO2.
Transient transfection, RNA interference, and cisplatin treatment
For plasmid transfection, HeLa cells were seeded in a 24-well plate at low densities overnight in RPMI 1640 supplemented with 10% FCS. Cells were transiently transfected at 70% to 90% confluency, using the plasmid DNA (up to 4 μg) mixed with the Lipofectamine 2000 reagent (Invitrogen) at the DNA (μg)/lipid (μL) ratio of 1:2.5. Silencing of GSK-3β was similarly performed with Si-GSk-3β plasmids in HeLa cells. At 4-6 h post-transfection, the plasmid- or siRNA-containing medium was replaced with normal culture medium containing 10% FCS, and the cells were incubated in a 5% CO2 incubator at 37°C. Transfected cells were then cultured in fresh medium for up to 12 to 48 h and harvested for gene expression and other assays. For specific blockage of GSK-3β activity, LiCl (20 mM) was added to HeLa cells simultaneously. For cisplatin treatment, various concentrations (0-10 μg/ml) of cisplatin were added to HeLa cells. DMSO alone and medium alone served as controls. Time point chosen for cisplatin addition to the transfected cells was 24 h after transfection, based on preliminary experiments.
Assessment of cell viability by MTT Assay
Treated or untreated cells were seeded into 96-well plates at 1 × 103 cells per well overnight and then incubated with different concentrations of cisplatin (from 0 to 10 μg/ml). After culture for 24 h, 20 μl of MTT dye solution (5 mg/ml) was added to each well, and samples were incubated at 37°C for 4 h. The formazan product was dissolved by adding 200 μL of DMSO to each well, and the plates were read at 570 nm. Cell growth activity was determined according to the formula for relative cell viability (OD570 from treated cells/OD570 from untreated cells ×100%). All measurements were done in triplicate, and the results were calculated from three independent experiments.
To determine the cytotoxicity of cisplatin and combination treatments of cisplatin and GSK-3β WT plasmid, HeLa cells were seeded onto 96-well plates at a density of 1 × 103 cells/well. Twenty-four hours later, the cells were transfected with GSK-3β WT plasmid at different concentrations (0, 1, 2, and 4 μg/ml). Cells treated with PBS were used as a control. Cisplatin at various concentrations (0-10 μg/ml) was also added to each well. The cells were incubated for 24 h, and cell growth and viability were analyzed by the MTT assay.
The effects of the combination treatment of PMS2 plasmid and cisplatin were analyzed with CalcuSyn software (Biosoft, Cambridge, UK) to determine the combination index (CI). Generally, it is considered that a CI <1.0 indicates synergism, CI = 1.0 indicates an additive effect, and CI >1.0 indicates antagonism.
Semi-quantitative RT-PCR analysis for PSM2 mRNA levels
Total RNA was isolated from HeLa cells after treatment with cisplatin (10 μg/ml), using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Total RNA (2 μg) was reverse transcribed using M-MuLV Reverse Transcriptase (Promega) and oligo(dT)18 as primer. cDNA was amplified by PCR using Taq DNA polymerase (Promega). The following primers were designed for RT-PCR: PSM2 forward 5'-GAG AAC CTG CTA AGG CCA TC-3', PSM2 reverse 5'-ATG GTG ACA TCG CTC AGT GC-3' (product size, 340 bp); β-actin forward 5'-ATC TGG CAC CAC ACC TTC CA-3' and reverse 5'-CTC CTT AAT GTC ACG CAC GA-3'(product size, 476 bp). All the primers were synthesized by Invitrogen. The thermocycling conditions were as follows: 30 s at 94°C, 45 s at 56°C, 30 s at 72°C, and 30 cycles followed by extension for 7 min at 72°C. PCR products were analyzed with 1.5% agarose gel electrophoresis in the presence of ethidium bromide for UV light transilluminator visualization. The relative PSM2 mRNA level was normalized to β-actin with Bio-Rad Quantity One 1-D Analysis Software (Bio-Rad). The experiment was repeated in triplicate.
Immunoprecipitation and Immunoblotting analysis
Treated and untreated HeLa cells were lysed for 10 min on ice with the same lysis buffer used for immunoblotting. Following centrifugation at 14,000 g for 10 min at 4°C, 1 ml of clear lysates was incubated with 5 μl of rabbit anti-GSK-3β antibody or 5 μl of normal goat IgG overnight with continuous rotation at 4°C. Protein A-sepharose beads (30 μl) were then added, and the samples were gently rocked 4°C for 3 h. After five washes with lysis buffer, the beads were recovered and resuspended in 40 μl of 2× SDS sample buffer (4% SDS, 0.125 mol/l Tris-HCl, 20% glycerol, and 0.04% bromphenol blue, pH 6.8) and then boiled for 5 min. The co-immunoprecipitation (IP) proteins dissociated from the beads were used for immunoblotting analysis.
Immunoblotting was done as previously described . Briefly, Treated and untreated HeLa cells were washed in cold PBS three times, and total cellular protein was extracted in 100 μl of RIPA lysis buffer (Pierce) at 4°C for 30 min. The protein concentration was determined by the Bradford method (Pierce). Samples containing 10 μg of protein were boiled and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% Tris-glycine gels and transferred electrophoretically to a polyvinylidene fluoride membrane. Primary antibodies (mouse anti-human PSM2, rabbit anti-human GSK-3β, and β-actin monoclonal antibody, 1:2,000) were used, followed by horseradish peroxidase-linked secondary antibody (goat anti-mouse IgG, 1:1,000) and visualized by Enhanced Chemiluminescence kits (Cell signaling). The relative density of PSM2 or GSK3β to β-actin was quantified with Bio-Rad Quantity One 1-D Analysis Software (Bio-Rad). The experiment was repeated in triplicate.
Treated and untreated HeLa cells in an eight-well Lab-Tek II Chamber Slide System (Nalge Nunc Int.; 70% confluence) were fixed with 4% paraformaldehyde in PBS followed by incubation in 0.5% Triton X-100 in PBS. After several washes, cells were blocked with 3% bovine serum albumin in PBS followed by incubation with mouse anti-PSM-2 (1:100) and rabbit anti-GSK-3β (1:100) antibodies at 4°C overnight in a humidified chamber. The cells were subsequently exposed to Texas red or FITC-labeled secondary antibodies (Santa Cruz Biotech) (1:200). The labeled cells were detected under a fluorescence microscope. Cells incubated with fluorescein-conjugated secondary antibodies in the absence of primary antibodies served as negative controls.
Apoptosis assay by flow cytometric analysis
Treated and untreated HeLa cells were stained with annexin-V and PI using a Vybrant Apoptosis Assay Kit (Invitrogen) according to the manufacturer's instructions. Briefly, HeLa cells were seeded onto 24-well plates for 24 h. The cells were then transfected with PMS2 plasmid (2 μg/ml). Various concentrations of cisplatin (0 or 10 μg/ml) were also added to each well. Cells treated with empty plasmid were used as a control. The cells were incubated for 24 h and were used for analyzing apoptosis and caspase-3 activity. For the apoptotic assay, HeLa cells were harvested and washed once with cold PBS. Cell pellets were re-suspended in 100 μL 1× annexin-binding buffer and 5 μL of FITC-annexin-V (component A), and 1 μL of the 100 μg/mL PI working solution was added to each 100 μL of cell suspension. The cells were incubated on ice for 1 h, washed with cold PBS once again, and re-suspended in 300 μL of 1× annexin-binding buffer, and the stained cells were analyzed for apoptosis by flow cytometry soon after staining.
Determination of caspase-3 activity
The activity of caspase-3 was measured using the caspase-3 activation kit (R&D systems, Inc., Minneapolis, MN), according to the manufacturer's protocol. Similar to the apoptotic assay, HeLa cells were transfected with PMS2 plasmid (2 μg/ml), and cisplatin of various concentrations (0-10 μg/ml) was also added. The cells were incubated for 0-36 h, and total protein in HeLa cells was extracted with RIPA lysis buffer and quantified by the Bradford method. One hundred micrograms of total protein was added to each well in 96-well microtiter plates (Bio-rad) with DEVD-pNA at 37°C for 1-2 h. The optical density of each well was measured at 405 nm using a microplate reader. Each plate contained multiple wells of a given experimental condition and multiple control wells. The activity of caspase-3 was expressed in arbitrary absorbance units (absorbance at a wavelength of 405 nm).
The Chi-square test was employed to analyze the positive rate of immunohistochemistric staining, and the correlation between pGSK-3β (s9) expression and MMR gene levels. Differences between different groups of HeLa cells in protein analysis, cell viability assays, and apoptosis studies were analyzed using ANOVA and a two-tailed t-test. The significance level was set at P < 0.05.
Expression of PMS2 and pGSK-3β in human cervical carcinoma tissues
Description of the patient population and biomarker expression
Patients (n = 78)
Age (Median ± SD)
47.2 ± 26.7
Primary tumor stages
Correlation between pGSK-3β (s9) expression and PMS2 expression in cervical carcinoma patients
x 2 value
P = 0.001
Cisplatin inhibits cell viability of HeLa cells and increases PMS2 production
Evidence indicates the interaction of GSK-3β and PMS2 in HeLa cells
To further determine the effect of GSK-3β activity on PSM2 production in HeLa cells, we divided HeLa cells into three groups and transfected them with GSK-3β WT, GSK-3β CA, or GSK-3β KD plasmids and harvested the cells 24 h after for immunoblotting analysis. We then compared PMS2 production in the different transfection groups by immunoblotting analysis. As illustrated in Figure 4B, our results show that PMS2 production in the GSK-3β WT and GSK-3β CA groups was significantly higher than that in the GSK-3β KD group and control, indicating that GSK-3β WT and GSK-3β CA plasmids were able to stabilize PMS2 production in HeLa cells (P < 0.05).
PMS2 transfection enhances chemosensitization of HeLa cells to cisplatin
The effect of combined PMS2 transfection and cisplatin therapy on the HeLa cells was also evaluated in our cell system. The cells were first transfected with PMS2 plasmid (0-4 μg/ml) and then exposed to cisplatin at various concentrations (0-10 μg/ml). Cells treated with empty plasmid were used as the control. Cell viability was determined at 24 h after treatment by using an MTT assay. We demonstrated a strong synergistic anti-tumor activity at the lower doses of the PMS2 plasmid (2-4 μg/ml) and cisplatin (4-10 μg/ml) in HeLa cells by CI (Figure 7B). The results therefore confirmed that PMS2 transfection improved chemosensitization of cisplatin on HeLa cells.
The significance of MMR in the development of cervical carcinoma has not been well documented, and few data are available. It is known that the role of the DNA MMR system is to maintain DNA replication fidelity by repairing DNA mismatches and insertion/deletion loops acquired during DNA replication . This process is highly conserved, from Escherichia coli to mammals. PMS2 is a major component of the DNA mismatch repair system. However, unlike other components, PMS2 is highly unstable and germline PMS2 mutations are rarely reported. PMS2 has recently emerged as an attractive target due to its low rate of mutation and unstabilization [20, 21], raising the possibility that certain types of exogenous DNA-damaging agents may rapidly degrade PMS2 production and disrupt the MMR system for facilitating carcinogenesis, and the rapid induction and degradation of PMS2 may be essential for the balance between cell survival and death as a sensor of environmental changes. In the present study, we found a significant PMS2 downregulation in human cervical carcinoma tissue, similar to the results found in other cancers. Moreover, we provide the first evidence that increased expression of phosphorylated GSK-3β (s9) (GSK-3β inactivation) is negatively correlated with PMS2 expression in cervical carcinoma and that GSK-3β is able to stabilize PMS2 production in HeLa cells, implicating a novel target to explore in the carcinogenesis and chemotherapy enhancement of human cervical carcinoma.
Irrespective of gene mutations, varied levels of MMR proteins have recently been reported in a variety of tumors, such as colon cancer, lung cancer, and breast cancer, that were responsible for the prognosis . A plausible explanation is that the disregulated DNA replication system is controlled and that no abnormal transcription of MMR protein occurs in normal cells, whereas in the abnormal tumor cells, MMR genes are rapidly activated and upregulated. Therefore, the loss of MMR activity due to rapid degradation may lead to less efficient gene repair, chemo-resistance and poor prognosis. To investigate the importance of MMR protein in this study, we firstly examined the expression of PMS2, MSH2 and MLH1 in cervical carcinoma by immunohistochemical staining. We found a significant downregulation of PMS2 in cervical carcinoma comparing to other protein. Furthermore, we detected PMS2 expression in cisplatin-induced HeLa cells and found a significant upregulation of mRNA and protein, compared to the control. The decrease of PMS2 activity in tissue and the induction of PMS production in HeLa cells suggested that the PMS2 protein may play a more important role in the development of cervical carcinoma.
Interestingly, we also found that PMS2 expression was negatively correlated with GSK-3β inactivation in tumor tissues, indicating that activated GSK-3β may stabilize PMS2 production directly. It is now clear that GSK-3β functions in diverse cellular processes including proliferation, differentiation, survival, neoplastic transformation and tumor development . The downstream targets of GSK-3β include some well-recognized genes such as Axin1, c-myc, β-catenin, snail, and MCL-1, which have a close association with carcinogenesis. Interestingly, all of them were found to share a similarity in structure by possessing the common motif of S/T XXX S/T. In our preliminary study, we found a consensus motif of VSSSH GPSDP TDRAE in PMS2 by gene sequencing. This finding indicated that PMS2 may be recognized by GSK-3β, and additional studies will be required to understand the interaction of GSK-3β and PMS2 in cervical carcinoma. This finding, together with the immunohistochemical results, raised the possibility that GSK-3β may be able to stabilize PSM2 production in cervical carcinoma. To prove our hypothesis, we transfected the GSK-3β gene into HeLa cells and evaluated the interaction of GSK-3β and PMS2 by using IP with an antibody to GSK-3β and immunoblotting with an antibody to PSM2. Surprisingly, we detected the PSM2 production in the IP complex, which provided the convincing evidence that GSK-3β is able to bind to PMS2 protein.
GSK-3β has become an important area of investigation as a key component of the Wnt signaling pathway. Unlike most protein kinases, GSK-3β is constitutively active in resting cells, and it undergoes a rapid and transient inhibition in response to a number of external signals. To investigate the interaction of GSK-3β and PMS2 in HeLa cells, we evaluated the effects of blocking GSK-3β activity using a GSK-3β KD plasmid, GSK-3β siRNA, and a specific inhibitor, LiCl, on the PMS2 production in HeLa cells. Consistently, our results showed that PMS2 production was downregulated in HeLa cells. And we observed a concentration-dependent reduction of PMS2 production in HeLa cells after administration of GSK-3β siRNA and Lithium. Furthermore, we observed co-location of GSK-3β and PMS2 protein in HeLa cells by indirect immunofluorescence staining, which was enhanced by transfection with GSK-3β WT and GSK-3β CA, but not GSK-3β KD. Taken together, these results provided evidence that GSK-3β is able to stabilize PMS2 production in HeLa cells.
Furthermore, it is very important to note that cervical cancer affects women at a higher incidence and a younger age, with the increased prevalence of human papillomavirus and alteration of socioeconimic condition , and prolonged cisplatin treatment appears to induce multiple mechanisms of tumor resistance . On the other hand, the MMR system is also implicated in the cellular response to DNA damage, and MMR deficiency was thought to be responsible for drug resistance during chemotherapy in a variety of cancers [26–28]. PMS2 are able to activate cell cycle checkpoints and apoptosis in response to persistent DNA damage . It is shown that PMS2 is required for cisplatin-induced activation of p73, a member of the p53 family of transcription factors with proapoptotic activity . However, the significance of PMS2 deficiency in drug resistance is controversial. Gibson et al. showed that dysregulation of PMS2 gene expression can disrupt MMR function in mammalian cells and establish an additional carcinogenic mechanism by which cells can develop genetic instability and acquire resistance to cytotoxic cancer therapies . In addition, Fedier et al. investigated the effects of loss of PMS2 on the sensitivity to a panel of widely used anticancer agents in E1A/Ha-Ras-transformed p53-null mouse fibroblasts either proficient or deficient in PMS2 and found that lack of the PMS2 gene is associated with an increased sensitivity to some types of anticancer agents such as cisplatin, oxaliplatin, and gemcitabine . To investigate whether loss of function of PMS2 plays a role in drug resistance in HeLa cells or not, we examined the effects of PMS2 transfection on apoptosis of HeLa cells induced by cisplatin using flow cytometry. We found that apoptotic cells and caspase-3 activity increased significantly, compared to the untreated cells. We also demonstrated a strong synergistic anti-tumor activity at lower doses of the PMS2 plasmid and cisplatin in HeLa cells by CI analysis. We therefore concluded that PMS2 upregulation significantly enhanced cisplatin-associated chemosensitivity, which may be useful for the treatment of cervical carcinoma. On the other hand, we confessed that our study contained some insufficiencies to investigate the associated mechanisms underlying MMR-deficiency in cervical carcinoma. The detailed mechanism underlying MMR-deficiency in cervical carcinoma is still not fully understood and other MMR components (MSH2, MLH1, MSH6) may be functional related with PMS2, which requires further study.
Our results provide the preliminary evidence that GSK-3β stabilized PMS2 production, which may play an important role in the carcinogenesis and chemotherapy of cervical carcinoma. This newly identified mechanism will be helpful in better understanding tumor development and in designing a novel therapeutic strategy for the treatment of human cervical carcinoma.
glycogen synthase kinase 3β
small interference RNA
transcription polymerase chain reaction
This work was supported by National Natural and Science Grant of China (No. 30801225). YZ and YS contributed equally to this study.
- Zhao EF, Bao L, Li C, Song L, Li YL: Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. Di Yi Jun Yi Da Xue Xue Bao. 2005, 25: 605-9.PubMedGoogle Scholar
- Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003, 83: S41-78. 10.1016/S0020-7292(03)90115-9.View ArticleGoogle Scholar
- Martin CM, Astbury K, O'Leary JJ: Molecular profiling of cervical neoplasia. Expert Rev Mol Diagn. 2006, 6: 217-29. 10.1586/14737188.8.131.52.View ArticlePubMedGoogle Scholar
- Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006, 7: 335-46. 10.1038/nrm1907.View ArticlePubMedGoogle Scholar
- Papadopoulos N, Lindblom A: Molecular basis of HNPCC: mutations of MMR genes. Hum Mutat. 1997, 10: 89-99. 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
- Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomäki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW: Analysis of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients. Nat Med. 1996, 2: 169-74. 10.1038/nm0296-169.View ArticlePubMedGoogle Scholar
- Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature. 1994, 371: 75-80. 10.1038/371075a0.View ArticlePubMedGoogle Scholar
- Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE: Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003, 98: 2199-206. 10.1002/cncr.11770.View ArticlePubMedGoogle Scholar
- Truninger K, Menigatti M, Luz J, Russell A, Haider R, Gebbers JO, Bannwart F, Yurtsever H, Neuweiler J, Riehle HM, Cattaruzza MS, Heinimann K, Schär P, Jiricny J, Marra G: Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology. 2005, 128: 1160-71. 10.1053/j.gastro.2005.01.056.View ArticlePubMedGoogle Scholar
- Nijhuis ER, Nijman HW, Oien KA, Bell A, ten Hoor KA, Reesink-Peters N, Boezen HM, Hollema H, Zee van der AG: Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. J Clin Pathol. 2007, 60: 824-30. 10.1136/jcp.2005.036038.View ArticlePubMedPubMed CentralGoogle Scholar
- Chung TK, Ip TY, Hampton GM, Wang VW, Cheung TH, Wong YF: Microsatellite instability in cervical carcinoma. Eur J Obstet Gynecol Reprod Biol. 2001, 94: 121-4. 10.1016/S0301-2115(00)00297-9.View ArticlePubMedGoogle Scholar
- Giarnieri E, Mancini R, Pisani T, Alderisio M, Vecchione A: Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Cancer Res. 2000, 6: 3600-6.PubMedGoogle Scholar
- Ciavattini A, Piccioni M, Tranquilli AL, Filosa A, Pieramici T, Goteri G: Immunohistochemical expression of DNA mismatch repair (MMR) system proteins (hMLH1, hMSH2) in cervical preinvasive and invasive lesions. Pathol Res Pract. 2005, 201: 21-5. 10.1016/j.prp.2004.09.012.View ArticlePubMedGoogle Scholar
- Chang DK, Ricciardiello L, Goel A, Chang CL, Boland CR: Steady-state Regulation of the Human DNA Mismatch Repair System. J Biol Chem. 2000, 275: 18424-31. 10.1074/jbc.M001140200.View ArticlePubMedGoogle Scholar
- Kim L, Kimmel AR: GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev. 2000, 10: 508-14. 10.1016/S0959-437X(00)00120-9.View ArticlePubMedGoogle Scholar
- Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qin J, Lai CC, Tsai FJ, Tsai CH, Huang MC: Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell. 2005, 19: 159-70. 10.1016/j.molcel.2005.06.009.View ArticlePubMedGoogle Scholar
- Li H, Wen W, Cheng L, Shi J, Jiang H, Oh Y, Xu G: Expression of chloride channel protein CLC-3 in patients with allergic rhinitis: effect of topical corticosteroid treatment. Arch Otolaryngol Head Neck Surg. 2008, 134: 301-5. 10.1001/archoto.2007.45.View ArticlePubMedGoogle Scholar
- Li HB, Cai KM, Liu Z, Xia JH, Zhang Y, Xu R, Xu G: Foxp3+ T regulatory cells (Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid. Clin Immunol. 2008, 129: 394-400. 10.1016/j.clim.2008.07.031.View ArticlePubMedGoogle Scholar
- Jascur T, Boland CR: Structure and function of the components of the human DNA mismatch repair system. Int J Cancer. 2006, 119: 2030-5. 10.1002/ijc.22023.View ArticlePubMedGoogle Scholar
- Hegan DC, Narayanan L, Jirik FR, Edelmann W, Liskay RM, Glazer PM: Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6. Carcinogenesis. 2006, 27: 2402-8. 10.1093/carcin/bgl079.View ArticlePubMedPubMed CentralGoogle Scholar
- Gill S, Lindor NM, Burgart LJ, Smalley R, Leontovich O, French AJ, Goldberg RM, Sargent DJ, Jass JR, Hopper JL, Jenkins MA, Young J, Barker MA, Walsh MD, Ruszkiewicz AR, Thibodeau SN: Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res. 2005, 11: 6466-71. 10.1158/1078-0432.CCR-05-0661.View ArticlePubMedGoogle Scholar
- Imai K, Yamamoto H: Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008, 29: 673-80. 10.1093/carcin/bgm228.View ArticlePubMedGoogle Scholar
- Forde JE, Dale TC: Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007, 64: 1930-44. 10.1007/s00018-007-7045-7.View ArticlePubMedGoogle Scholar
- Whiteside MA, Siegel EM, Unger ER: Human papillomavirus and molecular considerations for cancer risk. Cancer. 2008, 113 (10 Suppl): 2981-94.View ArticlePubMedGoogle Scholar
- Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM: Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Int J Gynecol. 2007, 17: 1194-204. 10.1111/j.1525-1438.2007.00900.x.View ArticleGoogle Scholar
- Martin LP, Hamilton TC, Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008, 14: 1291-5. 10.1158/1078-0432.CCR-07-2238.View ArticlePubMedGoogle Scholar
- Pani E, Stojic L, El-Shemerly M, Jiricny J, Ferrari S: Mismatch repair status and the response of human cells to cisplatin. Cell Cycle. 2007, 6: 1796-802.View ArticlePubMedGoogle Scholar
- Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology. 2004, 127: 1678-84. 10.1053/j.gastro.2004.10.001.View ArticlePubMedGoogle Scholar
- Marinovic-Terzic I, Yoshioka-Yamashita A, Shimodaira H, Avdievich E, Hunton IC, Kolodner RD, Edelmann W, Wang JY: Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. Proc Natl Acad Sci USA. 2008, 105: 13993-8. 10.1073/pnas.0806435105.View ArticlePubMedPubMed CentralGoogle Scholar
- Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY: Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA. 2003, 100: 2420-5. 10.1073/pnas.0438031100.View ArticlePubMedPubMed CentralGoogle Scholar
- Gibson SL, Narayanan L, Hegan DC, Buermeyer AB, Liskay RM, Glazer PM: Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Lett. 2006, 244: 195-202. 10.1016/j.canlet.2005.12.009.View ArticlePubMedGoogle Scholar
- Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D: Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer. 2002, 87: 1027-33. 10.1038/sj.bjc.6600599.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/58/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.